China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer
- China's NMPA accepted Akeso's application for ivonescimab with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer.
- The application previously received priority review designation.
- Phase III median overall survival reached 14.9 months with ivonescimab versus 12.1 months with durvalumab, both combined with chemotherapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611162230PR_NEWS_USPR_____CN99665) on November 17, 2026, and is solely responsible for the information contained therein.